DOD Biotech (BKK:DOD) provided clarifications to the Stock Exchange after reporting a net loss of 22 million baht in the first quarter, and auditor remarks over 141 million baht in deposits and advance payments.
The company said the transactions reflect a new expansion cycle tied to factory capacity constraints and demand outlook, according to a Thursday Thailand bourse filing.
The biotech firm said it made advance payments for a 72 million baht land deal, 20 million baht construction work, 47 million baht raw materials, 14 million baht machinery, and a 10 million baht wastewater upgrade.
DOD Biotech also addressed a 30 million baht cash advance involving a unit director, saying the amount has already been fully reimbursed, the filing said.